| 英文名稱 |
中文名稱 |
CAS號 |
操作 |
| SR4554 |
SR4554 |
167648-73-9 |
詳細(xì)
|
| Sulesomab |
硫索單抗 |
167747-19-5 |
詳細(xì)
|
| Felvizumab |
Felvizumab |
167747-20-8 |
詳細(xì)
|
| GNE-0946 |
GNE-0946 |
1677667-24-1 |
詳細(xì)
|
| Faralimomab |
Faralimomab |
167816-91-3 |
詳細(xì)
|
| (R)-VX-11e |
(R)-4-(2-((2-氯-4-氟苯基)氨基)-5-甲基嘧啶-4-基)-N-(1-(3-氯苯基)-2-羥基乙基)-1H-吡咯-2-甲酰胺 |
1680187-43-2 |
詳細(xì)
|
| DJ4 |
化合物DJ4 |
1681020-24-5 |
詳細(xì)
|
| PG 34 |
化合物 PG 34 |
1681056-62-1 |
詳細(xì)
|
| Propofol-d17 β-D glucuronide |
丙泊酚-D17Β-D-葡糖醛酸 |
1683581-05-6 |
詳細(xì)
|
| Rosmantuzumab |
Rosmantuzumab |
1684393-04-1 |
詳細(xì)
|
| Dyrk1A-IN-5 |
化合物 DYRK1A-IN-5 |
1685235-41-9 |
詳細(xì)
|
| Cynandione A |
1,1'-(2',3,6,6'-四羥基-[1,1'-聯(lián)苯]-2,3'-二基)二乙酮 |
168706-29-4 |
詳細(xì)
|
| YM-58790 |
化合物YM-58790 |
168830-70-4 |
詳細(xì)
|
| αvβ1 integrin-IN-1 |
化合物 T13473 |
1689540-62-2 |
詳細(xì)
|
| Flupyrimin |
N-[(E)-1-(6-氯-3-吡啶基)甲基-2(1H)-吡啶亞基]-2,2,2-三氟乙酰胺 |
1689566-03-7 |
詳細(xì)
|
| Obexelimab |
奧貝利單抗 |
1690307-05-1 |
詳細(xì)
|
| Lanepitant |
拉奈匹坦 |
170566-84-4 |
詳細(xì)
|
| ARTD10/PARP10-IN-1 |
ARTD10/PARP10抑制劑1 |
1708103-76-7 |
詳細(xì)
|
| 1-vinylpyrene |
1-乙烯 |
17088-21-0 |
詳細(xì)
|
| Frunevetmab |
夫盧維單抗 |
1708936-80-4 |
詳細(xì)
|
| Emapalumab |
依瑪魯單抗 |
1709815-23-5 |
詳細(xì)
|
| Sodium zirconium cyclosilicate |
環(huán)硅酸鋯鈉 |
17141-74-1 |
詳細(xì)
|
| Igovomab |
伊戈伏單抗 |
171656-50-1 |
詳細(xì)
|
| Piprozolin |
哌普唑林 |
17243-64-0 |
詳細(xì)
|
| tert-Butyl (6-iodohexyl)carbamate |
TERT-BUTYL 6-IODOHEXYLCARBAMATE |
172846-36-5 |
詳細(xì)
|
| Inophyllum E |
紅厚殼（種）內(nèi)酯 |
17312-31-1 |
詳細(xì)
|
| NDH-1 inhibitor-1 |
N-(3,4-二甲氧基芐基)-2-萘甲酰胺 |
173964-49-3 |
詳細(xì)
|
| (E)-3-(2-Chloro-4-fluorophenyl)acrylic acid |
AA |
174603-37-3 |
詳細(xì)
|
| Keliximab |
凱利昔單抗 |
174722-30-6 |
詳細(xì)
|
| Tidembersat |
TIDEMBERSAT |
175013-73-7 |
詳細(xì)
|
| BODIPY FL prazosin |
化合物 BODIPY FL PRAZOSIN |
175799-93-6 |
詳細(xì)
|
| Tagatose |
化合物 T34770 |
17598-81-1 |
詳細(xì)
|
| Roxifiban acetate |
化合物 T24733 |
176022-59-6 |
詳細(xì)
|
| CYP1B1-IN-5 |
CYP1B1抑制劑5 |
176442-56-1 |
詳細(xì)
|
| Izonsteride |
IZONSTERIDE |
176975-26-1 |
詳細(xì)
|
| 3,4,5-Trihydroxycinnamic acid decyl ester |
化合物 3,4,5-TRIHYDROXYCINNAMIC ACID DECYL ESTER |
1770778-45-4 |
詳細(xì)
|
| MMP2-IN-2 |
5-硝基-2-(4-硝基苯基)-1H-苯并咪唑 |
1772-39-0 |
詳細(xì)
|
| Phenmedipham-d3 |
甜菜寧-D3 |
1773497-41-8 |
詳細(xì)
|
| ATX-002 |
ATX-002 |
1777792-34-3 |
詳細(xì)
|
| Sarizotan 2HCl |
SARIZOTAN 2鹽酸鹽 |
177976-12-4 |
詳細(xì)
|
| Opaviraline |
奧帕韋蘭 |
178040-94-3 |
詳細(xì)
|
| Telisotuzumab |
Telisotuzumab |
1781223-80-0 |
詳細(xì)
|
| BMS-599626 2HCL(714971-09-2 Free base) |
化合物 BMS-599626 2HCL(714971-09-2 FREE BASE) |
1781932-33-9 |
詳細(xì)
|
| RKI-1447 dihydrochloride |
RKI 1447 dihydrochloride |
1782109-09-4 |
詳細(xì)
|
| ML 120B dihydrochloride |
MLN120B DIHYDROCHLORIDE |
1782573-78-7 |
詳細(xì)
|
| Xanthine amine congener hydrochloride |
N-(2-氨基乙基)-2-(4-(2,6-二氧代-1,3-二丙基-2,3,6,7-四氫-1H-嘌呤-8-基)苯氧基)乙酰胺鹽酸鹽 |
1783977-95-6 |
詳細(xì)
|
| LDN-209929 dihydrochloride |
化合物 LDN-209929 DIHYDROCHLORIDE |
1784281-97-5 |
詳細(xì)
|
| FK 866 hydrochloride (658084-64-1 free base) |
N-[4-(1-Benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide Hydrochloride |
1785666-54-7 |
詳細(xì)
|
| NLRP3/AIM2-IN-3 |
化合物 NLRP3/AIM2-IN-3 |
1787787-60-3 |
詳細(xì)
|
| Gosuranemab |
|
1788032-39-2 |
詳細(xì)
|
| UC-781 |
N-[4-chloro-3-(3-methylbut-2-enoxy)phenyl]-2-methyl-furan-3-carbothioamide |
178870-32-1 |
詳細(xì)
|
| Nav1.7-IN-3 |
NAV1.7-IN-3 |
1788872-06-9 |
詳細(xì)
|
| Basiliximab |
巴利昔單抗 |
179045-86-4 |
詳細(xì)
|
| WAY-639228 |
N-(1-芐基哌啶-4-基)萘-2-磺酰胺 |
179051-05-9 |
詳細(xì)
|
| Remtolumab |
壬托魯單抗 |
1791410-27-9 |
詳細(xì)
|
| Lutikizumab |
Lutikizumab |
1791411-57-8 |
詳細(xì)
|
| Elezanumab |
Elezanumab |
1791416-49-3 |
詳細(xì)
|
| Dilpacimab |
Dilpacimab |
1791420-09-1 |
詳細(xì)
|
| (2R,5S)-Ritlecitinib |
1792180-79-0 |
1792180-79-0 |
詳細(xì)
|
| Vunakizumab |
Vunakizumab |
1792181-33-9 |
詳細(xì)
|
| SB-237376 |
化合物 SB-237376 |
179258-59-4 |
詳細(xì)
|
| SB-237376 HCl |
Benzamide, N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitro-, hydrochloride (1:1) |
179258-62-9 |
詳細(xì)
|
| Porgaviximab |
Porgaviximab |
1792982-55-8 |
詳細(xì)
|
| Crizanlizumab |
Crizanlizumab |
1690318-25-2 |
詳細(xì)
|
| DP00477 |
化合物 DP00477 |
169120-56-3 |
詳細(xì)
|
| CCT245232 |
化合物 CCT245232 |
1693731-14-4 |
詳細(xì)
|
| SXC 2023 |
(R)-2-乙酰氨基-3-((4-甲基苯甲?；?硫基)丙酸 |
1695562-36-7 |
詳細(xì)
|
| Nonabine |
諾大麻 |
16985-03-8 |
詳細(xì)
|
| Anisperimus |
阿珀莫司 |
170368-04-4 |
詳細(xì)
|
| Cevidoplenib |
Methanone, cyclopropyl[5-[[4-[4-[[(4S)-4-hydroxy-2-isoxazolidinyl]methyl]-3-methyl-1H-pyrazol-1-yl]-2-pyrimidinyl]amino]-1-methyl-1H-indol-3-yl]- |
1703788-21-9 |
詳細(xì)
|
| NLRP3-IN-13 |
NLRP3 抑制劑 13 |
1704638-35-6 |
詳細(xì)
|
| AZ-PFKFB3-67 |
(2S)-N-[4-[[3-Cyano-1-[(3,5-dimethyl-4-isoxazolyl)methyl]-1H-indol-5-yl]oxy]phenyl]-2-pyrrolidinecarboxamide |
1704741-11-6 |
詳細(xì)
|
| Lanepitant 2HCl |
拉奈匹坦鹽酸鹽 |
170508-05-1 |
詳細(xì)
|
| Larcaviximab |
Larcaviximab |
1792982-56-9 |
詳細(xì)
|
| Cosfroviximab |
Cosfroviximab |
1792982-57-0 |
詳細(xì)
|
| ER-34122 |
化合物 ER-34122 |
179325-62-3 |
詳細(xì)
|
| Sacituzumab |
沙西妥珠單抗 |
1796566-95-4 |
詳細(xì)
|
| Netakimab |
Netakimab |
1796570-08-5 |
詳細(xì)
|
| PF-04822163 |
化合物 T28367 |
1798334-07-2 |
詳細(xì)
|
| GPR40 agonist 6 |
化合物 GPR40 AGONIST 6 |
1798751-25-3 |
詳細(xì)
|
| GNF6702 |
GNF-6702 |
1799329-72-8 |
詳細(xì)
|
| Thalidomide-O-amido-CH2-PEG3-CH2-NH-Boc |
THALIDOMIDE-O-AMIDO-CH2-PEG3-CH2-NH-BOC |
1799711-31-1 |
詳細(xì)
|
| GSK180 |
GSK180 |
1799725-26-0 |
詳細(xì)
|
| BCAT-IN-2 |
BCAT-IN-2 |
1800024-45-6 |
詳細(xì)
|
| Oleoylestrone |
雌酮 3-油酸酯 |
180003-17-2 |
詳細(xì)
|
| Vutiglabridin |
化合物 VUTIGLABRIDIN |
1800188-47-9 |
詳細(xì)
|
| Gremubamab |
GREMUBAMAB (格瑞巴單抗 ) |
1800381-36-5 |
詳細(xì)
|
| SR12418 |
化合物 SR12418 |
1801185-08-9 |
詳細(xì)
|
| Odronextamab |
奧尼妥單抗 |
1801338-64-6 |
詳細(xì)
|
| Cemiplimab |
Cemiplimab |
1801342-60-8 |
詳細(xì)
|
| RYL-552 |
化合物 T28636 |
1801444-56-3 |
詳細(xì)
|
| RYL-552S |
化合物 RYL-552S |
1801444-69-8 |
詳細(xì)
|
| Losatuxizumab |
Losatuxizumab |
1801544-27-3 |
詳細(xì)
|
| KL044 |
9H-Carbazole-9-acetamide, N-(2-chloro-6-cyanophenyl)- |
1801856-93-8 |
詳細(xì)
|
| Minzasolmin |
化合物 MINZASOLMIN |
1802518-92-8 |
詳細(xì)
|
| ZY-444 |
化合物 ZY-444 |
1802650-31-2 |
詳細(xì)
|
| ABBV-318 |
ABBV-318 |
1802848-94-7 |
詳細(xì)
|
| RN-1665 |
化合物 RN-1665 |
1803003-65-7 |
詳細(xì)
|
| Ravulizumab |
Immunoglobulin G2/G4, anti-(human complement C5) (human-Mus musculus ALXN1210 heavy chain), disulfide with human-Mus musculus ALXN1210 κ-chain, dimer |
1803171-55-2 |
詳細(xì)
|
| Oleclumab |
奧來魯單抗 |
1803176-05-7 |
詳細(xì)
|